8-KEarnings & ResultsExhibits & Filings

STRYKER CORP 8-K Report, Financial Results (Jul 19, 2011)

Filed July 19, 2011For Securities:SYK

Summary

Stryker Corporation filed an 8-K on July 19, 2011, to report its second quarter 2011 operating results. The key focus of this filing is the release of its quarterly earnings, which were accompanied by a press release detailing financial performance. Investors should note that Stryker is presenting both GAAP results and non-GAAP measures, such as "constant currency" sales and "adjusted diluted net earnings per share." The company utilizes these non-GAAP measures to provide a more comparable view of its performance, excluding the impact of foreign currency fluctuations and specific charges like acquisition and integration costs, asset impairments, and restructuring expenses. Notably, the filing includes projections for full-year 2011 adjusted diluted net earnings per share, estimated to be between $3.65 and $3.73. This projection factors in anticipated acquisition and integration-related charges stemming from recent acquisitions, including the Neurovascular division of Boston Scientific and Orthovita, Inc. Investors are encouraged to review the full press release, attached as Exhibit 99.1, for a comprehensive understanding of the reported results and the detailed reconciliations of non-GAAP measures.

Key Highlights

  • 1Stryker Corporation announced its second quarter 2011 operating results via an 8-K filing on July 19, 2011.
  • 2The company is reporting financial results using both Generally Accepted Accounting Principles (GAAP) and supplemental non-GAAP measures.
  • 3Key non-GAAP measures highlighted are 'constant currency' sales and 'adjusted diluted net earnings per share'.
  • 4These non-GAAP measures are used to provide a more comparable view of performance by excluding foreign currency impacts and specific charges.
  • 5The filing provides a reconciliation for projected full-year 2011 adjusted diluted net earnings per share, estimated between $3.65 and $3.73.
  • 6Acquisition and integration-related charges are expected in 2011 due to the recent acquisitions of Boston Scientific's Neurovascular division and Orthovita, Inc.
  • 7The press release detailing the results is attached as Exhibit 99.1 to the 8-K filing.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report Stryker Corporation's financial results for the second quarter of 2011 and to provide forward-looking guidance. It includes a press release that details the company's operational performance and financial condition.

'Constant currency' is a non-GAAP measure that removes the impact of foreign currency exchange rate fluctuations to present sales performance on a more comparable basis. 'Adjusted diluted net earnings per share' is a non-GAAP measure that excludes certain items like acquisition and integration-related charges, impairment charges, and other items that management believes affect the comparability of operating results, allowing for a clearer view of ongoing operational performance.

Stryker uses non-GAAP financial measures because management believes they provide meaningful information about the company's results on a consistent and comparable basis. These measures are used internally for business segment review, trend analysis, and bonus plan calculations, and the company believes they are useful for investors to evaluate period-to-period results and potential future operating results.

The filing mentions two recent acquisitions that will incur acquisition and integration-related charges during 2011: the Neurovascular division of Boston Scientific Corporation (completed January 3, 2011) and Orthovita, Inc. (completed June 27, 2011).